- freely available
- re-usable
Viruses 2009, 1(2), 144-165; doi:10.3390/v1020144
Review
Prophylactic and Therapeutic Vaccination against Hepatitis C Virus (HCV): Developments and Future Perspectives
Division of Viral Products, Center for Biologics, Food and Drug Administration, Bldg29A/Rm1D10, 8800 Rockville Pike, Bethesda, MD 20892, USA
Received: 3 June 2009; in revised form: 25 July 2009 / Accepted: 11 August 2009 / Published: 12 August 2009
(This article belongs to the Special Issue Hepatitis Viruses)
Abstract: Studies in patients and chimpanzees that spontaneously clear Hepatitis C Virus (HCV) have demonstrated that natural immunity to the virus is induced during primary infections and that this immunity can be cross protective. These discoveries led to optimism regarding prophylactic HCV vaccines and a number of studies in the chimpanzee model have been performed, all of which resulted in modified infections after challenge but did not always prevent persistence of the virus. Therapeutic vaccine strategies have also been pursued in an effort to reduce the costs and side effects associated with anti-viral drug treatment. This review summarizes the studies performed thus far in both patients and chimpanzees for prophylactic and therapeutic vaccination, assesses the progress made and future perspectives.
Keywords: vaccine; immune responses; immunotherapy; T cells; neutralizing antibody
Article Statistics
Click here to load and display the download statistics.Cite This Article
MDPI and ACS Style
Major, M.E. Prophylactic and Therapeutic Vaccination against Hepatitis C Virus (HCV): Developments and Future Perspectives. Viruses 2009, 1, 144-165.
AMA StyleMajor ME. Prophylactic and Therapeutic Vaccination against Hepatitis C Virus (HCV): Developments and Future Perspectives. Viruses. 2009; 1(2):144-165.
Chicago/Turabian StyleMajor, Marian E. 2009. "Prophylactic and Therapeutic Vaccination against Hepatitis C Virus (HCV): Developments and Future Perspectives." Viruses 1, no. 2: 144-165.
